SG11201408502XA - Method of purifying an antibody - Google Patents
Method of purifying an antibodyInfo
- Publication number
- SG11201408502XA SG11201408502XA SG11201408502XA SG11201408502XA SG11201408502XA SG 11201408502X A SG11201408502X A SG 11201408502XA SG 11201408502X A SG11201408502X A SG 11201408502XA SG 11201408502X A SG11201408502X A SG 11201408502XA SG 11201408502X A SG11201408502X A SG 11201408502XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- microweg
- nijmegen
- synthon
- designated states
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/062014 WO2013189544A1 (en) | 2012-06-21 | 2012-06-21 | Method of purifying an antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408502XA true SG11201408502XA (en) | 2015-01-29 |
Family
ID=46321045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408502XA SG11201408502XA (en) | 2012-06-21 | 2012-06-21 | Method of purifying an antibody |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9845338B2 (hr) |
| EP (1) | EP2864346B1 (hr) |
| KR (1) | KR101941742B1 (hr) |
| CN (1) | CN104487448B (hr) |
| CY (1) | CY1121394T1 (hr) |
| DK (1) | DK2864346T3 (hr) |
| ES (1) | ES2704487T3 (hr) |
| HR (1) | HRP20190030T1 (hr) |
| HU (1) | HUE043121T2 (hr) |
| LT (1) | LT2864346T (hr) |
| PL (1) | PL2864346T3 (hr) |
| PT (1) | PT2864346T (hr) |
| SG (1) | SG11201408502XA (hr) |
| WO (1) | WO2013189544A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7032046B2 (ja) * | 2016-01-22 | 2022-03-08 | 旭化成メディカル株式会社 | 生理活性物質の連続的な定流速精製方法 |
| US11149060B2 (en) | 2016-02-19 | 2021-10-19 | University Of Delaware | Functionalized nanoparticles for enhanced affinity precipitation of proteins |
| EP3769083A1 (en) | 2018-03-21 | 2021-01-27 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| EP3546475A1 (en) * | 2018-03-27 | 2019-10-02 | Sanofi | Full flow-through process for purifying recombinant proteins |
| KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
| AR119097A1 (es) * | 2019-06-05 | 2021-11-24 | Seattle Genetics Inc | Métodos de purificación de anticuerpos enmascarados |
| CN114539351B (zh) * | 2022-01-26 | 2023-03-03 | 上海健士拜生物科技有限公司 | 纳米抗体的纯化方法 |
| CN114409787A (zh) * | 2022-02-18 | 2022-04-29 | 南京英瀚斯生物科技有限公司 | 一种针对her3纳米抗体的分离纯化方法 |
| WO2023249892A1 (en) * | 2022-06-20 | 2023-12-28 | Amgen Inc. | Clearance of aggregates from uf/df pools in downstream antibody purification |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003062375A2 (en) * | 2001-12-19 | 2003-07-31 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
| US7553938B2 (en) * | 2004-02-27 | 2009-06-30 | Octapharma Ag | Method of providing a purified, virus safe antibody preparation |
| CA2574062A1 (en) * | 2004-07-20 | 2006-01-26 | Symphogen A/S | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
| SG170837A1 (en) * | 2006-04-05 | 2011-05-30 | Abbott Biotech Ltd | Antibody purification |
| RU2010130467A (ru) * | 2007-12-21 | 2012-01-27 | Дженентек, Инк. (Us) | Кристаллизация анти-cd20-антител |
| RU2514657C2 (ru) * | 2008-10-20 | 2014-04-27 | Эббви Инк, | Способ получения препарата антитела против il-18 или его антигенсвязывающей части (варианты) |
| BRPI1014774A2 (pt) * | 2009-04-27 | 2019-04-16 | Immuron Limited | preparacao de imunoglobulina enriquecida anti-lps para uso no tratamento e/ou na profilaxia de um disturbio patologico |
| AU2010261853B8 (en) * | 2009-06-15 | 2015-02-26 | Katholieke Universiteit Leuven, K.U. Leuven R&D | BACE1 inhibitory antibodies |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2011015920A2 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant trastuzumab |
| GB201012603D0 (en) * | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| US20120238730A1 (en) * | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Integrated approach to the isolation and purification of antibodies |
-
2012
- 2012-06-21 PT PT12728608T patent/PT2864346T/pt unknown
- 2012-06-21 SG SG11201408502XA patent/SG11201408502XA/en unknown
- 2012-06-21 KR KR1020157001645A patent/KR101941742B1/ko active IP Right Grant
- 2012-06-21 ES ES12728608T patent/ES2704487T3/es active Active
- 2012-06-21 CN CN201280074129.6A patent/CN104487448B/zh active Active
- 2012-06-21 US US14/410,562 patent/US9845338B2/en active Active
- 2012-06-21 LT LTEP12728608.6T patent/LT2864346T/lt unknown
- 2012-06-21 PL PL12728608T patent/PL2864346T3/pl unknown
- 2012-06-21 HU HUE12728608A patent/HUE043121T2/hu unknown
- 2012-06-21 WO PCT/EP2012/062014 patent/WO2013189544A1/en active Application Filing
- 2012-06-21 EP EP12728608.6A patent/EP2864346B1/en active Active
- 2012-06-21 DK DK12728608.6T patent/DK2864346T3/en active
-
2018
- 2018-12-20 CY CY20181101381T patent/CY1121394T1/el unknown
-
2019
- 2019-01-04 HR HRP20190030TT patent/HRP20190030T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2864346T3 (pl) | 2019-04-30 |
| KR101941742B1 (ko) | 2019-01-23 |
| CN104487448A (zh) | 2015-04-01 |
| HRP20190030T1 (hr) | 2019-02-22 |
| ES2704487T3 (es) | 2019-03-18 |
| US9845338B2 (en) | 2017-12-19 |
| CN104487448B (zh) | 2020-04-24 |
| HUE043121T2 (hu) | 2019-08-28 |
| CY1121394T1 (el) | 2020-05-29 |
| US20160002289A1 (en) | 2016-01-07 |
| DK2864346T3 (en) | 2019-02-04 |
| PT2864346T (pt) | 2018-12-12 |
| KR20150027807A (ko) | 2015-03-12 |
| LT2864346T (lt) | 2019-01-25 |
| EP2864346B1 (en) | 2018-10-17 |
| EP2864346A1 (en) | 2015-04-29 |
| WO2013189544A1 (en) | 2013-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408502XA (en) | Method of purifying an antibody | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201803900UA (en) | Process for preparing polyurea microcapsules with improved deposition | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201804398XA (en) | Method for producing rna molecule compositions | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201407774XA (en) | Conversion of biomass | |
| SG11201408224SA (en) | Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction | |
| SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201407233RA (en) | Ethylene oligomerization process | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201811336TA (en) | Method for producing an electrode catalyst from a perovskite metal oxide | |
| SG11201407427WA (en) | Extreme pcr | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
| SG11201407809QA (en) | Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201408396QA (en) | Improved resid hydrotreating catalyst containing titania | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds |